Medtronic Q1 FY2026: Revenue, operating profit rise; EPS flat amid large debt and legal risks

Medtronic plc (NYSE: MDT) - Q1 FY2026 snapshot

Straightforward view: revenue and operating profit expanded; EPS held flat; cash from operations is healthy but cash balance slid, debt remains large and litigation/hedging items add noise. Key numbers below.

Key facts & headline metrics
* Total net sales: $8,578M (Q1 FY26) vs $7,915M (Q1 FY25) - +8% YoY.
* Reportable segment net sales: $8,506M vs $7,967M - +7% YoY.
* Operating profit: $1,445M vs $1,278M.
* Net income attributable to Medtronic: $1,040M vs $1,042M (virtually flat).
* Diluted EPS: $0.81 (Q1 FY26) vs $0.80 (Q1 FY25).
* Operating cash flow: $1,088M; Free cash flow: $584M.
* Cash & cash equivalents: $1,273M (ending) - down from $2,218M at beginning of period; Current investments: $6,848M.
* Total assets: $90,972M; Total liabilities: $42,839M; Total shareholders' equity: $47,893M.
* Total debt (incl. current): ~$28.6B; long‑term debt reported $26,179M.
* Shares outstanding (Aug 20, 2025): 1,282,685,882; dividend paid this quarter: $910M.

Positive aspects (income statement & operations)
* Top-line growth across portfolios: Cardiovascular +9%, Diabetes +12%, Neuromodulation +10% - diversified revenue drivers.
* Operating profit improved to $1,445M, reflecting margin expansion versus prior year operating profit of $1,278M.
* Strong cash generation: $1,088M operating cash flow in the quarter and $584M free cash flow - supports dividends and repurchases.
* EPS roughly stable at $0.81 despite higher amortization and a higher tax rate - underlying non‑GAAP EPS was higher ($1.26 non‑GAAP).
* Balance sheet has sizable liquid investments ($6.8B) and maintains investment‑grade ratings (S&P A / Moody's A3).

Negatives / risks (income statement & items to watch)
* Net income essentially flat: $1,040M vs $1,042M - margin headroom limited given rising costs.
* Effective tax rate jumped to 19.6% (from 17.4%) - Pillar Two and jurisdictional mix pressure results.
* Significant non‑operating impacts and one‑offs: $459M amortization (including $45M accelerated), $113M net loss on minority investments (Mozarc-related), and certain litigation charges $27M (still ongoing legal exposure).
* Other operating expense, net rose to $70M (was $1M prior year) - largely currency/hedging and remeasurement effects.
* Cash balance declined by $945M in the quarter (driven by financing activity, debt repayments and dividend/repurchase cash), while total debt remains material (~$28.6B).
* Accumulated other comprehensive loss widened (AOCI more negative) driven by net investment hedge and cash flow hedge movements - potential volatility from FX/hedging.
* Pending separation of the Diabetes unit (announced May 2025) will create execution risk and transition costs; watch separation timeline and one‑time charges.

Operational takeaways - what to monitor next
* Execution of Diabetes separation (timing, costs, and impact on margins/liquidity).
* Litigation and regulatory matters (hernia mesh, pump retainer ring, antitrust) - potential future charges and cash outflows.
* FX and hedging volatility - AOCI and other operating expense items have shown quarter volatility.
* Debt maturities and commercial paper usage (cash flows, interest environment) given large outstanding senior notes.
* Continued adoption of growth platforms: Micra, Evolut TAVR, PulseSelect/Affera, MiniMed 780G and Neuromodulation franchises - these drive organic growth.

Bottom line: Medtronic is growing revenue and operating profit while producing solid cash flow, but EPS is flat after higher non‑operating charges (minority investment losses, amortization) and a higher effective tax rate. The balance sheet remains large and liquid but carries meaningful long‑term debt and exposure to legal, hedging and separation execution risks. Investors should track Diabetes separation progress, litigation updates, FX/hedge mark‑to‑market swings, and debt/cash flow dynamics.